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ABSTRACT
Venom immunotherapy (VIT) is proven to be curative for insect allergy, but the mechanisms and the biomark-
ers associated with clinical efficacy remain elusive. We report herein the discovery of a leading candidate
biomarker, osteopontin (OPN), for VIT. From cDNA microarray and clustering analyses, an increased expres-
sion of OPN was found in patients who completed 5―6 years of VIT and discontinued therapy for 3―6 years as
compared with the untreated group. A significantly higher level of serum OPN was found in the completed treat-
ment group as compared with the untreated group. Following VIT, kinetically increased levels of OPN associ-
ated with reduced venom specific IgE levels were noted in subjects with large local allergic reactions to venom.
These findings together with the fact that OPN is involved in Th1-associated immune response strongly sug-
gest a role of OPN as a functional biomarker for VIT.
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INTRODUCTION
Venom immunotherapy (VIT) proves to be the most
effective in insect allergy.1-3 However the regulatory
mechanisms by which immunotherapy achieves its
sustained clinical efficacy remain elusive , and the
biomarkers associated with efficacious immunother-
apy have not yet been identified. As part of a genom-
ics study to identify candidate biomarkers associated
with successful VIT, we have identified that a promis-
ing candidate, osteopontin (OPN), was up-regulated
after the start therapy.4,5 In this review, we summa-
rize the series of experiments in which we identified
OPN as a potential biomarker for the efficacy of VIT
through the use of cDNA microarray analysis . We
also summarize the reported functions of OPN in im-
mune responses, which suggest the potential involve-
ment of OPN in the mechanisms of VIT and in the
IgE-mediated allergic responses.
VENOM IMMUNOTHERAPY
Allergen-specific immunotherapy is a method of
modulating the clinical reactivity of the patient and is
the most effective therapy for insect allergy. VIT is
generally effective with less than 3 months’ treat-
ment, but persistent tolerance seems to develop after
4 years or more of treatment.1,2 There are no criteria
to identify the point in time when protection becomes
long-lasting. In addition, despite the remote possibil-
ity of severe reaction, the supervised sting challenge
test is the only available means to evaluate the effi-
cacy of VIT. For specific treatment to protect high-
risk patients and for others to be able to avoid or stop
treatment with impunity, there is a critical need to
identify the markers that can be used to predict out-
come or to derive biological insight into the mecha-
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Fig. 1 Cluster analysis of 1751 genes with ＞＿ 2.0-fold changes; early treat-
ment (ET) versus untreated (Unt) or completed treatment (CT) versus un-
treated (Unt). 
A, Cluster image of cDNA microaray expression profiles of 1751 genes. 
The ratio of gene expression levels is represented according to the color 
scale shown (red, upregulation; blue, downregulation).
B, Expression profiles of individual genes in cluster A and B. The X-axis indi-
cates the fold change of upregulation or downregulation compared with the 
intensity of the untreated group.
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nism of successful VIT.
During maintenance VIT, a modest reduction in se-
rum allergen-specific IgE , concomitant with an in-
crease in allergen-specific IgG, 6 particularly of the
IgG4 isotype,7 has been reported. However, the level
of venom-specific IgG antibodies is not an absolute
predictor of the outcome of a sting challenge , be-
cause in patients who are treated for more than 4
years, even those with low venom-IgG levels do not
react to stings.8 This observation suggests that im-
mune tolerance to venom becomes established
through a non-IgG mechanism after extended mainte-
nance therapy.
While the evidence accumulated to date has re-
vealed that VIT is associated with many changes in
immune cells and cytokines, such as Th2 to Th1 cy-
tokine shift9 and the induction of T-cell anergy associ-
ated with elevated levels of IL-10,10 the mechanism of
action has so far remained elusive.3 This is due, in
part, to the fact that the focus has been on the cytoki-
nes and mechanisms associated with protection from
sting reactions in the early stage of immunotherapy.
Identification of relevant targets that are predictive of
long-term clinical outcome is needed for the clinical
utility and understanding of the mechanisms for the
efficacy of VIT.
DISCOVERY OF A CANDIDATE
BIOMARKER, OSTEOPONTIN, FOR VENOM
IMMUNOTHERAPY THROUGH THE USE OF
CDNA MICROARRAY
To identify differentially expressed genes and poten-
tial biomarker(s) associated with VIT, gene expres-
sion profiles of peripheral blood mononuclear cells
(PBMCs) from patients with and without VIT were
compared using cDNA microarray analysis. The gene
expression profiles from the untreated (Unt) group (3
patients) served as the baseline for comparisons with
the early (3 subjects on VIT for less than 1 year) (ET)
and completed ( 3 subjects who completed 5 to 6
years of VIT) (CT) treatment groups. A total of 1751
genes with2.0-fold changes were selected and sub-
sequently used for hierarchical clustering. Candidate
clusters were selected by querying the gene expres-
sion data set , derived from the study groups for
genes that demonstrate an overall pattern of progres-
sively increasing (or decreasing) expression concor-
dant with different stages of VIT (Fig. 1) . Among
those genes differentially expressed, OPN emerged
as the leading candidate with higher level of differen-
tial expression following VIT, particularly in subjects
after 5 to 6 years of successful VIT (1.6-fold, ET ver-
sus Unt; 7.0-fold , CT versus Unt) , which was vali-
dated by real-time PCR assays. Monocytes were the
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Fig. 2 Upregulated genes that are known to be associated with 
OPN. These genes were identified in clusters A and B shown in Fig-
ure 1.
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Fig. 3 (A) Serum OPN levels are higher in patients from the completed treatment group 
(CT) than in the untreated group (Unt). The line represents the median value of each pa-
tient group.(B) Kinetic changes of serum OPN levels after the start of VIT.
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dominant cell population in the PBMCs expressing
OPN, because depletion of monocytes significantly
reduced the level of OPN expression. It is noted that
a group of genes encoding products known to be in-
volved in the OPN regulatory pathway was also iden-
tified in the same clusters (Fig. 2 ) . For example ,
these include CD44 (a receptor for OPN), ITGA4 (in-
tegrin α4, a receptor for OPN), IFNGR1, IFNGR2
(interferon-γ receptor), MRC1 (mannose receptor, C
type 1), and PLAU (urokinase type plasminogen acti-
vator, inducible by OPN). Further, the genes encod-
ing cytokine receptors, such as TNFR2 (TNF-α re-
ceptor), CSF2RB (GM-CSF receptor), and IL1R1,
IL1R2 (IL-1 receptor), and their associated signaling
molecules were also identified in these clusters (Fig.
2).
OSTEOPONTIN AS A POTENTIAL
BIOMARKER FOR THE EFFICACY OF
VENOM IMMUNOTHERAPY
To further confirm differential expression of OPN
and to test the hypothesis that OPN is a functional
biomarker of VIT, serum levels of OPN were ana-
lyzed in a panel of 16 subjects randomly chosen from
the CT group and 16 from the Unt group. As seen in
Figure 3A, significantly higher levels of OPN were
found in the CT group than those seen in the Unt
group (Mann-Whitney U test, p < 0.001).
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To obtain longitudinal measurement of serum OPN
levels after VIT, a total of 8 subjects with large local
allergic reactions, but not systemic allergic reactions
after sting challenge, were recruited. This group of
patients received initial and maintenance VIT accord-
ing to current practice parameters as previously re-
ported,11,12 from which longitudinal data and specific
outcome assessment ( sting challenge ) were avail-
able. This group of patients had demonstrable, but
variable levels of reduction in skin reactivity to bee
sting challenge after VIT, and the majority of patients
responded well to VIT as early as 2 months after VIT.
Serum samples were collected at various time points
before VIT (Pre) and at 2 (2 mo), 6 (6 mo), 12 (12
mo), and 24 (24 mo) months after the start of VIT,
and the levels of serum OPN were analyzed for all 8
subjects . As shown in Figure 3B , a significant in-
crease in the levels of OPN with time-dependent up-
ward trend was found over the 2-year period of VIT
compared with those detected before VIT (p < 0.05 vs
Pre in all cases). The difference was particularly sig-
nificant at 12 mo and 24 mo, whereas no significant
change was seen at an earlier time point (2 mo). It is
often noted that the levels of serum IgE tend to in-
crease shortly after the start of VIT and gradually de-
cline over the course of long-term VIT. This trend
was clearly evident for the majority of study subjects
receiving VIT. It is noted that although the patterns
of kinetic change were variable among the study sub-
jects , the levels of OPN showed an inverse trend
compared with the levels of IgE over the course of
VIT (Fig. 3B).
OSTEOPONTIN
OPN, also known as Eta-1 (early T lymphocyte activa-
tion protein 1) or as SPP1 (secreted phosphoprotein
1) contains functional domains for extracellular ma-
trix adhesion. It has been implicated in a number of
physiological and pathological events and have re-
cently been shown to play a role in T cell-mediated
immunity.13-16 While the mechanistic aspect of OPN
function remains to be defined, it appears that OPN
mediates cell-matrix interactions and cellular signal-
ing through binding with integrin and CD44 recep-
tors , 16 involving both RGD-dependent and RGD-
independent interactions. Expression of OPN is con-
stitutive in bone and at epithelial surfaces, and it is
upregulated in activated T cells, natural killer (NK)
cells, macrophages, Kupffer cells and tumor cells in
models of inflammation, ischemia-reperfusion, bone
resorption, and tumor progression.17-19 Also, high lev-
els of OPN have been observed in several Th 1-
associated diseases, including rheumatoid arthritis20
and multiple sclerosis (MS).21 Increased expression
of OPN has also been found in granulomatous re-
sponses,22 a typical Th1 immune response, and in pul-
monary fibrosis.23
EFFECT OF OSTEOPONTIN ON IgE-
MEDIATED ALLERGIC RESPONSES
Given the fact that a reciprocal regulation of Th1 vs
Th2 responses is a well-documented phenomenon, it
is tempting to speculate that the known Th1-inducing
activity of OPN may potentially play a role in modulat-
ing the allergic responses via its Th1-inducing activ-
ity. However, the direct involvement of OPN in Th2-
associated allergic responses has not been investi-
gated.
Although studies of various OPN-deficient mouse
models have provided evidence for the importance of
OPN in the development of Th1-associated immune
responses,21,24-26 the precise mechanism is still un-
clear. It is noted that in primary cultures of PBMCs,
we found no functional effects of OPN (native or re-
combinant form) on Th1Th2 cytokine expression in
vitro using human PBMCs.27 We concluded that re-
ported cytokine-inducing activity of OPN was entirely
due to the contamination of endotoxin. In addition,
human IgE synthesis from purified B cells in vitro
was also unaffected by the addition of varying doses
of OPN (unpublished data). Further studies are still
needed to clarify the pathophysiological mechanisms
by which OPN affects Th1Th2 immune responses.
Of interest, a significant reduced level of OPN is as-
sociated with hyper-IgE syndrome.28 Moreover, we
identified that OPN gene polymorphisms are associ-
ated with serum total IgE level in a Japanese popula-
tion. 29 Individuals carrying the C allele at position
5891 in exon 6, which is more prevalent in patients
with MS in the Japanese population30 displayed sig-
nificantly lower levels of total serum IgE compared
with non-carriers of this allele. Individuals homozy-
gous for the C allele at position 7052 in exon 7, which
is associated with development of SLE,31 exhibited
significantly higher total serum IgE levels than carri-
ers of the 7052T allele . Patients with MS, a Th1-
immune disease, display significantly fewer allergic
symptoms , a lower number of allergen sensitiza-
tions32 and reduced risk of asthma33 than individuals
without MS. Conversely, SLE is characterized by Th2
immune responses, and some reports have shown in-
creased IgE production in SLE and have associated
SLE with allergy.34 The results of these genetic stud-
ies indicate the potential involvement of OPN in IgE-
mediated allergic responses.
CONCLUSION
OPN is now recognized as a key cytokine involved in
Th1 immune responses. However, the data exploring
the direct role of OPN in IgE-mediated allergic re-
sponses are scanty. The data shown in this review
suggest a potential role for OPN in the IgE-mediated
allergic responses. Further studies with large num-
bers of patients are required to evaluate the utility of
serum OPN as a functional marker of VIT. Further
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functional studies are also clearly needed to define
the role of OPN in allergic responses.
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